Main Reference
Cancer

Subscribe to Multiple Myeloma

PHASE 2 STUDY OF PF-06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA

Cancer Internal Medicine Multiple Myeloma Adult Subjects Female Subjects Male Subjects

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects wit…

Cancer Internal Medicine Immunology Multiple Myeloma Immunodeficiency Adult Subjects Female Subjects Male Subjects

The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel \[cilta-cel\]) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).

Rising Tide - Zometa in Chondrosarcoma (JAH)

Cancer Internal Medicine Multiple Myeloma Sarcoma Adult Subjects Female Subjects Male Subjects

The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.

High dose ascorbic acid in Multiple Myeloma

Cancer Internal Medicine Multiple Myeloma Adult Subjects Female Subjects Male Subjects

This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.